BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
UCB plans to submit regulatory applications in Q3 2022
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Subscribe To Our Newsletter & Stay Updated
